[NOAC in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease]
1Skånes Universitetssjukhus - Kärlkliniken Malmö, Sweden - , Sweden.
Abstract:
New oral anticoagulants (NOAC) have been introduced in Swedish health care as first line treatment of atrial fibrillation and venous thromboembolism. NOAC have also been studied in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease, and reduced doses will presumably emerge as routine treatment also in these conditions.
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
13:10Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA
Published on: April 24, 2017
Related Concept Videos
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Peripheral Artery Disease I: Introduction
Coronary Artery Disease V: Interprofessional Care
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease IV: Preventive Measures
